SIBN - NASDAQ
SI-BONE, Inc.
$13.92
-0.64%SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
At a Glance
Live SnapshotSI-BONE, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
SI-BONE, Inc. Cash Flow Statement
SIBN • NASDAQ
| SI-BONE, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||
-18.9M | -30.9M | -43.3M | -61.3M | -56.6M | -43.7M | -38.4M | -17.5M | -23M | -20.6M | -28.2M | -27.8M | -6.2M | -10.9M | |
2.7M | 4.4M | 5.4M | 3.5M | 2.1M | 1.1M | 774K | 722K | 1M | 1M | 786K | 287K | 50K | 42K | |
0.0 | 0.0 | 0.0 | 0.0 | 3.6M | 0.0 | -1.2M | 664K | 2M | 1.3M | -201K | -199K | -1.3M | 4.1M | |
25.5M | 25.9M | 24.1M | 23.1M | 16.9M | 11.9M | 7.5M | 2.3M | 1.4M | 1.4M | 1.2M | 804K | 515K | 433K | |
4.3M | -1.6M | -29K | 730K | 288K | 2.5M | 259K | 259K | 722K | 299K | 5.1M | 444K | 2.2M | -3.9M | |
-14.3M | -10.1M | -4.8M | -7.6M | -5.8M | -2.5M | -479K | -1M | 382K | -198K | -1.4M | -56K | 2.8M | -4.5M | |
-675K | -12.4M | -18.7M | -41.7M | -39.5M | -30.7M | -31.6M | -14.5M | -17.5M | -16.8M | -26.7M | -26.3M | -566K | -14.8M | |
INVESTING ACTIVITIES | ||||||||||||||
-8.4M | -10.5M | -7.8M | -9.5M | -6.4M | -2.6M | -2.4M | -942K | -478K | -441K | -2.2M | -2.9M | -735K | -39K | |
(0.0) | (0.0) | (0.0) | (0.0) | -58M | (0.0) | -15.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-192.5M | -205.4M | -189.5M | -119.5M | -102M | -179.2M | -143.9M | -96.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
205.1M | 228.5M | 137.5M | 126.2M | 160M | 118.8M | 159.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 58M | 0.0 | 15.9M | -96.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(4.2M) | (12.6M) | -59.8M | -2.8M | (51.6M) | -62.9M | (13.5M) | -97.8M | -478K | -441K | -2.2M | -2.9M | -735K | -39K | |
FINANCING ACTIVITIES | ||||||||||||||
3.4M | 0.0 | 83.7M | 2.2M | 4.9M | 138M | 0.0 | 115.5M | 0.0 | -3K | 21.4M | 33.1M | 53K | 0.0 | |
0.0 | 0.0 | 725K | 0.0 | -6.6M | -750K | 0.0 | 0.0 | 13.7M | 4M | 10M | 5M | 8M | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2.2M) | -73K | (0.0) | -3K | (0.0) | (0.0) | -45K | (0.0) | |
0.0 | 2M | 6.5M | 0.0 | 0.0 | -843K | 3.5M | -356K | -6.3M | 433K | 20K | 5K | 7K | 4M | |
3.4M | 2M | 90.9M | 2.2M | -1.7M | 136.4M | 3.5M | 115.2M | 12.9M | 24.8M | 31.4M | 38.1M | 8.1M | 4M | |
CASH FLOW SUMMARY | ||||||||||||||
431K | -479K | 132K | -429K | -498K | 323K | -37K | -94K | -346K | 67K | 247K | 183K | -3K | -22K | |
7.3M | 1.7M | 12.6M | -42.7M | 9.8M | 43.1M | -14.7M | 2.7M | -5.5M | 7.6M | 2.7M | 9.1M | 6.8M | -10.8M | |
34.9M | 33.3M | 20.7M | 63.4M | 53.6M | 10.4M | 25.1M | 22.4M | 27.9M | 20.3M | 17.6M | 8.5M | 1.8M | 12.5M | |
42.2M | 34.9M | 33.3M | 20.7M | 63.4M | 53.6M | 10.4M | 25.1M | 22.4M | 27.9M | 20.3M | 17.6M | 8.5M | 1.8M | |
-9.1M | -22.9M | -26.5M | -51.2M | -45.9M | -33.2M | -34.1M | -15.5M | -18M | -17.2M | -29M | -29.2M | -1.3M | -14.8M |
SEC Filings
SIBN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 21, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 05, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 04, 2025 | July 31, 2025 | 2025 |
Related Guides
Continue your SIBN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.